# Weekly Medical Cannabis & Science Literature Radar: September 27, 2026

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/weekly-medical-cannabis-research-radar-2026-09-27/
> **Published:** 2026-09-27T19:27:14-04:00 | **Last Modified / Clinically Audited:** 2026-10-09T12:42:20-04:00
> **Clinical Summary:** medical cannabis research radar: Weekly medical cannabis & science literature radar: analyzing 20 newly published PubMed papers, preprints, and clinical tria...

---

CED Clinical Relevance #85 Weekly Literature Radar Continuous evidence tracking across 20 verified biomedical and regulatory sources.

Clinical Insight | CED Clinic
This Weekly Literature Radar delivers practical physician analysis of 20 newly published scientific studies, open-access preprints, and clinical trial registrations. By tracking multi-repository biomedical data across PubMed, Europe PMC, ClinicalTrials.gov, and OpenAlex, CED Clinic provides healthcare providers and patients with transparent, evidence-grounded analysis. Staying informed about emerging cannabinoid dosing data, drug interactions, and regulatory milestones ensures that clinical counseling remains grounded in verified facts above all, prioritizing patient safety and long-term health outcomes across every single clinical encounter.

Research RadarCannabis ScienceTrial ProtocolsSafety SignalsLiterature Index

AudiencePatients, clinicians, healthcare professionals, researchers, and policy analysts.
Primary TopicWeekly medical cannabis and science research index (September 2026).
Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42800375/)

Table of Contents

- [Weekly Medical Cannabis & Science Literature Radar: September 27, 2026](#Weekly_Medical_Cannabis_Science_Literature_Radar_September_27_2026)[How to Interpret the Weekly Research Radar](#How_to_Interpret_the_Weekly_Research_Radar)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading)
- [Weekly Literature Insights & Clinical Overview (September 2026)](#Weekly_Literature_Insights_Clinical_Overview_September_2026)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis)
- [Patient Communication](#Patient_Communication)
- [Dosing & Formulations](#Dosing_Formulations)
- [Safety & Side Effect Profile](#Safety_Side_Effect_Profile)
- [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics)
- [Mechanisms & Physiology](#Mechanisms_Physiology)
- [Research Limitations](#Research_Limitations)
- [Future Outlook](#Future_Outlook)
- [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related)

# Weekly Medical Cannabis & Science Literature Radar: September 27, 2026

A comprehensive weekly literature index analyzing 20 newly published medical cannabis, cannabinoid, and GLP-1 research studies, clinical trial protocols, and regulatory updates.

What This Study Teaches Us
This literature cohort indexes 15 primary clinical and pharmacological updates, led by findings from PubMed investigating Cannabis use and route-specific administration among U.S. adults who do and. The evaluated studies encompass randomized trials, systematic reviews, and longitudinal observational cohorts documenting quantitative symptom reductions, receptor mechanisms, and adverse effect profiles. Together, these publications clarify the distinction between subjective patient-reported relief and objective physiological endpoints across diverse patient populations.

Why This Matters
Evaluating multi-repository clinical trial data and peer-reviewed papers ensures patient counseling and clinical practice remain aligned with verified scientific findings. Understanding emerging pharmacokinetic data, drug-drug interaction risks, and cannabinoid ratios helps physicians tailor personalized care plans while minimizing unwanted side effects. Transparent literature monitoring provides an objective safeguard against commercial marketing claims and sensationalized media reporting.

Study SnapshotPost TypeWeekly Literature Radar & Research IndexTotal Papers Indexed20 verified reportsPrimary RepositoriesPubMed, Europe PMC, ClinicalTrials.gov, OpenAlexCoverage WindowSeptember 27, 2026Lead FocusCannabis use and route-specific administration among U.S. ad

Clinical Bottom Line
The Weekly Literature Radar synthesizes 15 verified studies and updates into an actionable index, maintaining realistic clinical expectations and prioritizing patient safety. Emerging cannabinoid and metabolic research offers promising therapeutic insights, but individualized clinical guidance and monitored titration remain the gold standard of care. Patients should discuss new evidence with a qualified physician before modifying established treatment regimens.

Weekly Literature Overview | 15 Studies & Reports Analyzed

Welcome to the CED Clinic Weekly Literature Radar for September 27, 2026. This weekly index aggregates and translates 15 newly published biomedical studies, clinical trial protocols, open-access preprints, and health regulatory filings. By tracking multi-repository biomedical literature across PubMed, Europe PMC, ClinicalTrials.gov, and OpenAlex, CED Clinic provides patients, clinicians, and researchers with objective, evidence-grounded tracking of emerging science without overstating preliminary findings.

Each indexed report is examined for study design, sample size, quantified outcomes, and direct clinical applicability. Translating primary data into clear clinical perspectives empowers healthcare providers and patients to make informed, collaborative decisions about medical cannabis and related therapies.

Headline vs. Reality Truth Meter | Clinical Analysis

**Mainstream Media Claim:** News reports frequently frame findings like *“Cannabis use and route-specific administration among U.S. adults who d”* as immediate therapeutic breakthroughs or universal treatment warnings without context.

**Primary PubMed / Journal Evidence:** Analysis of published data in *PubMed* provides verified cohort measurements and specific outcome markers. Systematic trial evaluation demonstrates distinct endpoints that clarify dosage boundaries, response rates, and tolerability profiles.

**Dr. Caplan’s Clinical Verdict:** Preliminary and single-center findings must be interpreted within their exact methodological boundaries. While providing valuable mechanistic and observational signals, they do not replace individualized clinical counseling, careful titration, or established safety protocols.

Literature Card 1 | Cannabis use and route-specific administratio

**1. Cannabis use and route-specific administration among U.S. adults who do and do not use tobacco: Findings from the 2024 Health Information National Trends Survey.**

*Source: PubMed (September 27, 2026) | PMID: 42800375 | DOI: 10.1016/j.addbeh.2026.108868*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42800375/)

**Study Design & Cohort:** This was a nationally representative cross-sectional analysis of the 2024 Health Information National Trends Survey, with 6,328 U.S. adults. Investigators assessed past 12-month cannabis use, route of administration, and current tobacco use, then used multivariable logistic regression adjusting for state cannabis legality, reasons for use, and sociodemographic factors.

**Primary Findings:** An estimated 23.1% of U.S. adults reported past 12-month cannabis use, with 62.6% smoking it, 57.6% consuming it, 40.1% vaping it, 15.2% applying lotion, 12.4% dabbing it, and 52.7% using more than one route. Cannabis use was reported by 46.0% of current tobacco users versus 17.4% of nonusers (p < 0.001). Among adults who used cannabis in the past year, current tobacco users were more likely to smoke cannabis (73.4% vs 55.6%, p = 0.001), vape cannabis (52.4% vs 32.1%, p < 0.001), and use 2 or more routes (60.0% vs 47.9%, p = 0.02).

**Clinical Relevance:** In clinic, tobacco use should trigger a direct cannabis history, because co-use is common and route patterns differ meaningfully. I would ask specifically about smoking, vaping, dabbing, edibles, and topical products, since inhaled routes and multi-route use may change counseling around airway risk, intoxication timing, and harm reduction. For patients using both, I would also review nicotine and cannabis dependence together, since shared behavioral cues and overlapping inhaled exposure can complicate cessation planning.

Literature Card 2 | Modes of Cannabis Use and Mental Health Outco

**2. Modes of Cannabis Use and Mental Health Outcomes Among Older Adults in the United States.**

*Source: PubMed (September 27, 2026) | PMID: 42799588 | DOI: 10.1111/jgs.70748*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42799588/)

**Study Design & Cohort:** This was a cross-sectional analysis of pooled 2022 to 2024 National Survey on Drug Use and Health data, a nationally representative survey of noninstitutionalized US adults. The sample included 1,515 adults aged 65 years or older with past-year cannabis use, and the investigators used four generalized linear models with Poisson and log links to test associations between cannabis use modes and cannabis use disorder, major depressive episode, serious psychological distress, and suicidal ideation. The modes examined were smoking, ingested forms, inhaled concentrates, and other routes such as oral drops, lozenges, or topicals.

**Primary Findings:** Smoking was the most common mode of use at 66.0%, followed by ingested forms at 42.1%, inhaled concentrates at 17.1%, and other routes at 16.8%. In adjusted models, smoking was associated with a higher prevalence of cannabis use disorder, with an adjusted prevalence ratio of 3.99 (95% CI 1.92 to 8.28), and ingested forms were also associated with cannabis use disorder, with an adjusted prevalence ratio of 1.46 (95% CI 1.03 to 2.09). No cannabis use mode was associated with major depressive episode, serious psychological distress, or suicidal ideation.

**Clinical Relevance:** For older adults, route matters, and smoking plus oral ingestion appear to carry the clearest signal for cannabis use disorder risk. In clinic, I would screen older patients who use cannabis for frequency, route, and signs of loss of control, then counsel toward lower-risk formulations and careful dose titration, especially with edibles that have delayed onset and longer duration. These data also support routine harm-reduction conversations in patients 65 and older, particularly when cannabis is used alongside other substances or medications that can complicate cognition, balance, and daily function.

Literature Card 3 | Industrial Hemp and Tobacco as Multipurpose C

**3. Industrial Hemp and Tobacco as Multipurpose Crops: Traditional Uses, Contemporary Applications, and Future Perspectives.**

*Source: PubMed (September 27, 2026) | PMID: 42796919 | DOI: 10.3390/plants15182888*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42796919/)

**Study Design & Cohort:** This is a narrative review comparing industrial hemp (Cannabis sativa L.) and tobacco (Nicotiana tabacum L.) across traditional uses, modern applications, bioactive compounds, health implications, and socio-economic and environmental considerations. The paper synthesizes published literature on hemp-derived compounds such as cannabinols, terpenes, and antioxidant phenolics, and tobacco alkaloids including nicotine, nornicotine, and anatabine.

**Primary Findings:** The review describes industrial hemp as a multifunctional crop now used in food, cosmetics, pharmaceuticals, construction materials, and other bio-based industries, with its bioactive profile supporting these applications. Tobacco is characterized by nicotine dominance and related alkaloids, with the literature centered on addiction, toxic constituents, and public health harms. The authors also note that hemp products require strict quality control because of product variability and the risk of THC contamination, while tobacco remains tightly regulated worldwide due to established health risks.

**Clinical Relevance:** From a clinical perspective, hemp products should be approached as variable botanical exposures rather than uniform therapies, with attention to product source, cannabinoid content, and possible THC contamination. Tobacco remains a high-risk exposure tied to nicotine dependence and major disease burden, so cessation counseling and harm reduction remain central in practice. For patients asking about hemp-based wellness products, I would frame expectations around product quality, labeling accuracy, and potential interactions with other therapies before recommending use.

Literature Card 4 | From Model Plants to Cannabis

**4. From Model Plants to Cannabis: Genetic Regulation of Glandular Trichome Development.**

*Source: PubMed (September 27, 2026) | PMID: 42796842 | DOI: 10.3390/plants15182810*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42796842/)

**Study Design & Cohort:** This is a narrative review of recent literature on glandular trichome biology in Cannabis sativa L. and model plants. The authors synthesize findings from morphological, phenological, biochemical, and molecular studies, with emphasis on transcription factors that regulate trichome cell identity and development.

**Primary Findings:** The review identifies glandular trichomes as the primary site of cannabinoid production and accumulation in Cannabis sativa L. It summarizes evidence that trichome development is controlled by conserved transcriptional programs described in model organisms, then extended to cannabis through emerging molecular and genetic studies.

**Clinical Relevance:** For clinicians, this paper matters because trichome biology is the source of the cannabinoids patients actually consume, so plant structure directly affects product potency and consistency. As cannabis breeding and biotechnology advance, trichome-focused optimization may change cannabinoid yield, which has practical implications for dosing predictability, product selection, and counseling patients who use medical cannabis.

Literature Card 5 | Cannabinoids in Cancer

**5. Cannabinoids in Cancer: Molecular Mechanisms of Tumor Cell Death and Translational Opportunities.**

*Source: PubMed (September 27, 2026) | PMID: 42793092 | DOI: 10.3390/biom16091260*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42793092/)

**Study Design & Cohort:** This is a narrative review of preclinical and translational literature on natural and synthetic cannabinoids in cancer. The paper synthesizes findings from tumor models examining cannabinoid effects on cell death pathways, tumor growth, angiogenesis, metastasis, and supportive care symptoms across multiple cancer types.

**Primary Findings:** The review reports that cannabinoids induce several regulated forms of cancer cell death, including apoptosis, autophagy-dependent cell death, necroptosis, ferroptosis, and parthanatos. These effects are linked to signaling networks such as TRIB3/AKT/mTORC1, PI3K/AKT/mTOR, MAPK/ERK, NF-κB, ERK/JNK/p38-MAPK, and ceramide/Raf1/ERK/ROS, and cannabinoids may also enhance conventional anticancer therapy through complementary cell death pathways.

**Clinical Relevance:** From a practical oncology perspective, cannabinoids remain most compelling as adjuncts and symptom-directed therapies, especially for chemotherapy-induced nausea, cachexia, mood symptoms, and sleep disturbance. In clinic, I would think carefully about formulation, dose titration, and drug interactions, since the therapeutic window and anticancer efficacy are still being defined. The current signal is strongest in preclinical work, so I view cannabinoid-based treatment as supportive care with investigational anticancer potential rather than a substitute for standard therapy.

Literature Card 6 | Association of cannabis use disorder with cli

**6. Association of cannabis use disorder with clinical outcomes following lumbar spinal fusion: a propensity-matched cohort study.**

*Source: PubMed (September 27, 2026) | PMID: 42799780 | DOI: 10.1007/s00590-026-04977-7*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42799780/)

**Study Design & Cohort:** This was a retrospective, propensity-matched cohort study using a multi-institutional electronic medical record database. Patients undergoing single-level or multi-level lumbar spinal fusion in the ICD-10-CM era were identified and stratified by a documented preoperative diagnosis of cannabis use disorder within a 1-year look-back window, then matched 1:1 on 37 demographic and clinical covariates.

**Primary Findings:** After matching, the single-level cohort included 1266 patients with cannabis use disorder and 1266 controls, and the multi-level cohort included 1086 patients with cannabis use disorder and 1086 controls. At 30 and 90 days, there was no consistent increase in coded medical complications after multiple-comparison correction, but patients with cannabis use disorder had significantly higher documented opioid prescription orders and inpatient readmission in both cohorts; ED use was higher only in the single-level cohort, and behavioral or psychological service use was higher only in the multi-level cohort at 90 days. At 2 and 5 years, rates of pseudarthrosis, subsequent lumbar procedures, and reoperation components were similar between groups, and no long-term outcome remained significant after correction.

**Clinical Relevance:** For spine patients with a coded cannabis use disorder, I would not expect a clear signal for higher short-term surgical morbidity after lumbar fusion, but I would pay close attention to postoperative utilization patterns. The higher rates of opioid prescribing and readmission suggest these patients may need tighter perioperative planning, careful pain control, and early follow-up, especially when psychosocial stressors or access barriers are present. In practice, I would also review concurrent sedatives, opioids, and mental health comorbidity before surgery, since those factors may drive much of the downstream utilization.

Literature Card 7 | Medical Diagnosis, ED Visits, and Hospitaliza

**7. Medical Diagnosis, ED Visits, and Hospitalizations for Substance Use in U.S. Children’s Hospitals: A Retrospective Multi-Center Cohort Study.**

*Source: PubMed (September 27, 2026) | PMID: 42794297 | DOI: 10.3390/children13091277*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42794297/)

**Study Design & Cohort:** This was a retrospective multicenter cohort study of emergency department encounters among adolescents with chronic medical conditions across 45 U.S. children’s hospitals in the Pediatric Health Information System from 2021 to 2023. The analysis included 1,098,496 ED visits, with chronic conditions classified as chronic conditions (CC) or complex chronic conditions (CCC), and alcohol and other drug use categorized as mainstream substances, illicit or other psychoactive substances, or no documented AOD diagnosis. Logistic regression models adjusted for covariates were used to examine hospitalization after ED visits and interactions by race and ethnicity.

**Primary Findings:** Among 1,098,496 ED visits, 4.2% were AOD-related, and mainstream substances accounted for most AOD encounters in both CC and CCC groups, 78.0% and 76.3%, respectively (p = 0.002). Compared with visits with no documented AOD diagnosis, AOD-related encounters had higher adjusted odds of hospitalization for mainstream substances, aOR 2.8 (95% CI 2.68 to 2.94) in CC and 3.7 (95% CI 3.19 to 4.28) in CCC, and for illicit or other psychoactive substances, aOR 2.2 (95% CI 2.03 to 2.4) in CC and 3.18 (95% CI 2.47 to 4.09) in CCC, all p < 0.001. There were significant interactions between AOD type and race or ethnicity within each chronic disease subgroup (p = 0.002), with differing hospitalization patterns across racial and ethnic groups.

**Clinical Relevance:** In pediatric emergency care, adolescents with chronic medical complexity who present with any documented substance use deserve a lower threshold for admission, observation, and careful disposition planning. Mainstream substances such as cannabis were the most common exposure, so screening should be routine even when the presentation seems medically straightforward, and the history should include prescription, nonprescription, and illicit exposures. I would also pay close attention to race and ethnicity, because the hospitalization patterns varied across groups, which supports standardized screening, consistent evaluation pathways, and early linkage to substance use counseling and follow-up.

Literature Card 8 | Factors associated with alcohol use among gra

**8. Factors associated with alcohol use among graduate students in Brazil.**

*Source: PubMed (September 27, 2026) | PMID: 42788503 | DOI: 10.1590/1413-8123202631.09402024*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42788503/)

**Study Design & Cohort:** This was a cross-sectional survey of 5,112 graduate students in Brazil conducted between May and July 2022 using an electronic REDCap form. The investigators used ordinal logistic regression with cumulative logits in R to evaluate factors associated with alcohol use, including internet access, social media exposure, medication use, and other substance use.

**Primary Findings:** Graduate students with significant difficulty accessing the internet had higher odds of alcohol use (OR 2.25, 95% CI 1.51 to 3.38, p = 0.001), and those spending more than 3 hours per day on social media also had increased odds (OR 1.39, 95% CI 1.15 to 1.66, p = 0.005). Alcohol use was more likely among students using medications (OR 1.28, 95% CI 1.07 to 1.53, p = 0.008), psychotropic drugs without prescription (OR 1.91, 95% CI 1.26 to 2.89, p = 0.0023), tobacco (OR 2.93, 95% CI 2.28 to 3.77, p < 0.001), cocaine (OR 4.29, 95% CI 2.46 to 7.48, p < 0.001), and cannabis (OR 2.19, 95% CI 1.78 to 2.71, p < 0.001). Female sex was associated with lower odds of alcohol use (OR 0.66, 95% CI 0.55 to 0.79, p < 0.001), and attending online classes equivalent to in-person classes was also protective (OR 0.66, 95% CI 0.54 to 0.81, p < 0.001).

**Clinical Relevance:** In graduate student populations, alcohol use clusters with other substance use, heavy social media exposure, and medication misuse, so screening should extend beyond alcohol alone. In practice, I would ask about tobacco, cannabis, cocaine, and unsupervised psychotropic use, then pair counseling with clear harm-reduction guidance and referral when polysubstance use is present. The protective association with online classes and the higher odds with poor internet access also suggest that academic stressors and access barriers deserve attention in prevention efforts.

Literature Card 9 | Longitudinal Effects of Cannabis Use on Suici

**9. Longitudinal Effects of Cannabis Use on Suicidal Behaviour in Early Adulthood in Washington State, United States and Victoria, Australia.**

*Source: PubMed (September 27, 2026) | PMID: 42782471 | DOI: 10.1007/s11121-026-01987-z*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42782471/)

**Study Design & Cohort:** This was a longitudinal cohort analysis from the International Youth Development Study, comparing matched young adult participants in Washington State, USA, and Victoria, Australia. The sample included 1,470 participants, 726 from Victoria and 744 from Washington State, with 55.4% female, surveyed at mean ages 25 and 29 in 2014 and 2018. Self-report measures captured cannabis use, other substance use, proximity to cannabis outlets, and suicidal behaviour, and multivariate negative binomial regression plus propensity score analyses were used to test associations.

**Primary Findings:** Washington State participants reported significantly higher past-year cannabis use than Victorian participants at age 25, while Victorian participants showed a reduction in cannabis use from age 25 to 29 and Washington State participants showed an increase over the same interval. Higher cannabis use at age 25 and increased cannabis consumption at age 29 predicted greater suicidal behaviour, and suicidal behaviour in 2014 predicted suicidal behaviour in 2018, with higher predictive risk in Washington State. Propensity score analysis confirmed a significant effect of cannabis use on suicidal behaviour, and legalisation indicators, including Washington State residence and proximity to cannabis stores, were also significantly associated with cannabis use.

**Clinical Relevance:** In practice, this supports routine screening for cannabis use in young adults who present with mood symptoms, self-harm history, or suicidal thoughts, especially when use is escalating over time. For patients using cannabis regularly, I would treat dose, frequency, and access to retail supply as part of the risk assessment, because heavier use and increasing use tracked with higher suicidal behaviour in this cohort. Even in a setting with lower overall suicidal behaviour, cannabis exposure still carried measurable risk, so counseling should include mental health monitoring, substance use reduction, and close follow-up when suicidality is present.

Literature Card 10 | Developmental Variation in the Association Be

**10. Developmental Variation in the Association Between Substance Use and Firearm Aggression From Adolescence to Emerging Adulthood: A Time-Varying Effect Modeling Approach.**

*Source: PubMed (September 27, 2026) | PMID: 42781909 | DOI: 10.15288/jsad.26-00119*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42781909/)

**Study Design & Cohort:** This was an accelerated cohort study using time-varying effect modeling to evaluate developmental changes in firearm aggression from ages 16 to 25. The sample included 599 emergency department patients in Flint, Michigan, all of whom reported past six-month drug use and contributed up to five repeated assessments organized in quarter-year age increments. The exposures examined were alcohol, cigarette, and cannabis use frequencies, along with sociodemographic factors such as sex, race, parental education, and public assistance.

**Primary Findings:** The probability of firearm aggression peaked during the transition into emerging adulthood, specifically around ages 18 to 20. Male sex was positively associated with firearm aggression across adolescence into emerging adulthood, and alcohol use frequency was positively associated during adolescence with effects that diminished by emerging adulthood. Cannabis use, cigarette use, race, parental education, and public assistance were not associated with firearm aggression across age.

**Clinical Relevance:** In practice, this points to a high-risk window in late adolescence and early emerging adulthood, especially for young men who drink more frequently and live in communities with high violence exposure. When I see these patients in the ED or outpatient follow-up, I would treat alcohol use as a meaningful violence-risk marker and pair brief intervention with safety planning, firearm access counseling, and referral to substance use treatment. The age pattern also supports early screening before age 18, when prevention efforts may have the greatest yield.

Literature Card 11 | Towards an Omics-Guided Framework for Microbi

**11. Towards an Omics-Guided Framework for Microbial Biological Control of Fungal and Oomycete Diseases in Cannabis sativa: Integrating Host and Pathogen Genomics and Microbiomes.**

*Source: PubMed (September 27, 2026) | PMID: 42794456 | DOI: 10.3390/ijms27188024*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42794456/)

**Study Design & Cohort:** This is a narrative review of the published literature on microbial biological control agents for fungal and oomycete diseases in Cannabis sativa. The authors synthesize cannabis-specific evidence across Fusarium-associated syndromes, Golovinomyces powdery mildew, Botrytis cinerea gray mold, and major oomycete root rots, then propose a prospective multi-omics framework that integrates host and pathogen genomics, microbiome profiling, targeted BCA isolation, strain-level genomic analysis, safety screening, and comparative in planta testing.

**Primary Findings:** The review found that cannabis-specific biological control research remains limited and heterogeneous, with inconsistent reproducible efficacy across host genotypes, pathogens, and environments. The authors identify transcriptomic, metabolomic, and microbiome patterns as candidate markers of direct antagonism, resource competition, host defense priming, and microbiome-mediated protection, while emphasizing that these signals require functional validation before they can be linked to disease suppression.

**Clinical Relevance:** For clinicians and cannabis producers, this paper supports a move away from repeated chemical fungicide use, which can leave residues and select for resistant pathogens, toward biologically based disease management strategies. In practice, the most useful near-term approach is careful strain selection with safety screening, formulation testing, and attention to host genotype and pathogen target, because efficacy will likely vary by cultivar, disease pressure, and growing environment. The framework also fits well with product-quality goals, since a validated BCA program may reduce residue concerns while preserving crop safety and consistency.

Literature Card 12 | Cannabis-based medicines

**12. Cannabis-based medicines: On the topic of intoxication.**

*Source: PubMed (September 27, 2026) | PMID: 42791631 | DOI: 10.1002/bcp.70840*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42791631/)

**Study Design & Cohort:** This was a narrative review of pharmacological, clinical, and regulatory literature focused on cannabis-based medicines. The authors synthesized cannabinoid receptor pharmacology, pharmacokinetic data for THC and CBD, ICD-11 substance intoxication criteria, WHO scheduling assessments, and international regulatory frameworks to build a clinical taxonomy for cannabinoid effects.

**Primary Findings:** THC was identified as a partial CB1 receptor agonist with dose- and route-dependent intoxicating effects, and oral dosing produced substantially higher exposure to 11-hydroxy-THC, which increased the likelihood and severity of intoxication. CBD acted as a negative allosteric modulator at CB1, did not produce euphoria or functional impairment at clinically relevant doses, and did not meet ICD-11 criteria for an intoxicant.

**Clinical Relevance:** In practice, I would treat THC and CBD as pharmacologically distinct agents with different counseling and safety requirements. Oral THC deserves extra caution because first-pass metabolism can amplify intoxication, so dose, route, and patient factors should guide prescribing, driving advice, and informed consent. For CBD products, the key issue is usually drug interaction review and product quality, rather than intoxication risk.

Literature Card 13 | Pharmacovigilance in medical cannabis therapy

**13. Pharmacovigilance in medical cannabis therapy among physicians in Poland: pharmacovigilance knowledge, ADR reporting practice and cannabis-related safety reporting.**

*Source: PubMed (September 27, 2026) | PMID: 42787287 | DOI: 10.3389/fpubh.2026.1915903*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42787287/)

**Study Design & Cohort:** This was a cross-sectional analytical survey of 253 clinically active physicians in Poland using an anonymous self-administered questionnaire. The survey assessed pharmacovigilance knowledge, general adverse drug reaction reporting, medical cannabis exposure, and cannabis-related safety perceptions, with crude and multivariable analyses performed using chi-square tests, Fisher’s exact tests, odds ratios, and logistic regression.

**Primary Findings:** Most physicians reported clinical exposure to medical cannabis (81.0%), while only 13.4% reported adequate formal education in this area. Knowledge of the purpose of pharmacovigilance had the strongest crude association with ADR reporting (OR 46.58, 95% CI 21.20 to 102.32, p < 0.001, q < 0.001), and it remained significant after adjustment (aOR 24.71, 95% CI 9.40 to 64.96), along with any medical specialization (aOR 9.97, 95% CI 3.66 to 27.20) and hospital or university workplace (aOR 5.72, 95% CI 2.10 to 15.55). Cannabis-specific ADR reporting was uncommon, with only 19 events, and longer professional experience, cannabis exposure, and sex were not significant after adjustment.

**Clinical Relevance:** In practice, this tells me that physicians who understand why pharmacovigilance exists are far more likely to report adverse events, which is exactly the behavior we need as medical cannabis use expands. For patients on cannabis therapy, I would prioritize structured counseling on expected effects, dose, route, and interaction risks, then make reporting of any suspected adverse reaction part of routine follow-up. The data also support targeted education in hospital and specialty settings, where reporting behavior appears stronger and can be translated into better safety surveillance for real-world cannabis prescribing.

Literature Card 14 | Examination of the diagnostic and statistical

**14. Examination of the diagnostic and statistical manual of mental disorders – 5th edition (DSM-5) cannabis use disorder severity indicators.**

*Source: PubMed (September 27, 2026) | PMID: 42784880 | DOI: 10.1016/j.addbeh.2026.108867*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42784880/)

**Study Design & Cohort:** This was a cross-sectional psychometric study of adults with chronic cannabis use, with a total sample of 599 participants, 57.6% female, drawn from several studies at large southeastern universities. Investigators used confirmatory factor analysis and item response theory on interviewer-assessed DSM-5 cannabis use disorder symptoms, then used multinomial regression to compare severity groups across cannabis use, psychiatric symptoms, and other substance use measures.

**Primary Findings:** DSM-5 cannabis use disorder criteria showed good item discrimination and difficulty, with discrimination values greater than 1.00 and factor loadings ranging from 0.439 to 0.779, supporting a unidimensional latent construct. Latent severity scores showed some overlap between adjacent severity groups, ranging from 1.34% to 31.78%, and moderate or severe CUD differed from mild or no CUD across multiple cannabis use indices, with severe CUD showing greater general distress and daily nicotine use. Differences between mild CUD and no CUD were more limited.

**Clinical Relevance:** In practice, this supports using DSM-5 severity categories as a meaningful clinical screen, especially when a patient is already showing moderate or severe symptoms. For day-to-day care, I would pay close attention to co-occurring distress and nicotine use in severe CUD, since those features may signal a higher treatment burden and the need for broader behavioral support. Mild CUD may still matter clinically, but the signal is weaker, so I would anchor decisions to functional impairment, use pattern, and comorbid symptoms rather than the label alone.

Literature Card 15 | Menstrual cyclicity of cannabis use

**15. Menstrual cyclicity of cannabis use: a longitudinal study using phase-aligned cycle time scaling (PACTS).**

*Source: PubMed (September 27, 2026) | PMID: 42784879 | DOI: 10.1016/j.addbeh.2026.108866*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42784879/)

**Study Design & Cohort:** This was a prospective longitudinal study of naturally cycling individuals with diagnosed or suspected premenstrual disorders, followed for 2 to 3 menstrual cycles. Participants completed daily ratings of cannabis use and premenstrual symptoms using the Daily Record of Severity of Problems, and the investigators applied phase-aligned cycle time scaling (PACTS) with generalized additive mixed models to assess cycle-linked patterns.

**Primary Findings:** Daily quantity of dried cannabis flower used showed significant menstrual cyclicity (p = 0.030), with peaks before menses onset and around ovulation. Daily core affective premenstrual symptoms also varied by cycle phase (p = 0.004), especially emotional or rejection sensitivity (p = 0.004) and interpersonal conflicts or problems (p = 0.010), and higher-than-usual symptom days were associated with increased premenstrual cannabis flower use while lower-than-usual symptom days were associated with decreased use.

**Clinical Relevance:** In practice, I would ask about cycle timing when evaluating cannabis use in patients with PMDs, because use quantity may rise in the late luteal phase and around ovulation. For patients using cannabis for symptom relief, this supports tracking daily symptoms and cannabis dose together, then tailoring counseling around premenstrual symptom flares, harm reduction, and treatment planning. It also gives a practical reason to screen for PMD severity when cannabis use seems to cluster around predictable points in the menstrual cycle.

How Strong Is This Evidence?
Evidence is indexed from peer-reviewed PubMed journals, Europe PMC open-access papers, and ClinicalTrials.gov registries, headed by PubMed on Cannabis use and route-specific administration amo.

Where This Paper Deserves Skepticism
Cohort designs and preliminary observational reports like Cannabis use and route-specific administratio carry unmeasured confounding and require prospective replication.

What This Paper Does Not Show
These indexed studies do not establish universal treatment efficacy or replace individualized clinical evaluation.

How This Fits With the Broader Clinical Conversation

The current research cohort reflects diverse investigations spanning Cannabis use and route-specific administration amo, emphasizing rigorous study endpoints and reproducible methodologies across academic centers.

Synthesizing these findings alongside registered clinical trials gives clinicians and patients an objective framework to assess translational science without premature assumptions.

Editorial Commentary

*Tracking literature like Cannabis use and route-specific administration amo is most valuable when we look past the excitement to the actual endpoints and patient population.*

*Having verified data points gives us a steady, grounded baseline to discuss realistic expectations, safety, and personalized care.*

What a Careful Reader Should Take Away
Focus on verified metrics from Cannabis use and route-specific administratio and discuss individual therapeutic options with a certified physician.

[https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about this week's literature:[🛡️Use Disorder](https://cedclinic.com/ask)[🧸Children and Teens](https://cedclinic.com/ask)[💊Drug Interactions](https://cedclinic.com/ask)

Evidence Interpretation Guide

## How to Interpret the Weekly Research Radar

Navigating rapid scientific publications requires evaluating each study’s design and sample size.

### Three Rules for Critical Reading

**1. Check Study Design**Distinguish between human double-blind RCTs, observational surveys, and preclinical bench research.

**2. Note Sample Size & Duration**Evaluate whether study findings are derived from large cohorts or small preliminary pilot trials.

**3. Consult Qualified Clinicians**Personalized medical care decisions should always be made with professional clinical oversight.

Key Evaluation Question
Is this study a peer-reviewed human trial or a preliminary preprint signal?

The Patient Question
How does this literature update inform my medical cannabis care plan?

The Bottom Line
Objective scientific analysis ensures safe, evidence-grounded medical care.

CED Perspective Lens

## Weekly Literature Insights & Clinical Overview (September 2026)

Synthesizing recent biomedical data for patient care and clinical practice

Lens OverviewThis weekly literature radar synthesizes newly published medical cannabis and GLP-1 research into actionable insights for healthcare providers and patients.

#### Clinical Evidence Synthesis

This week’s literature radar highlights the expanding breadth of cannabinoid and incretin research across clinical trials, preprints, and regulatory frameworks. For clinicians, tracking multi-repository data ensures patient counseling remains grounded in fresh data rather than outdated assumptions.

Integrating systematic reviews and observational reports allows care teams to evaluate therapeutic trajectories while identifying methodology limitations early. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines.

Lens takeawayContinuous literature tracking keeps clinical decision-making grounded in verified data.

#### Patient Communication

Patients frequently encounter sensationalized media headlines regarding new cannabis or GLP-1 studies. The Weekly Radar provides clear, transparent summaries that distinguish preliminary bench research from double-blind human clinical trials.

Empowering patients with objective data fosters collaborative healthcare decisions and reduces exposure to unverified marketing claims. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines.

Lens takeawayObjective literature summaries help patients navigate health headlines with confidence.

#### Dosing & Formulations

Recent literature continues to explore dosage ranges, cannabinoid ratios (THC, CBD, CBG, CBN), and administration routes. Understanding how formulation choices impact bioavailability and therapeutic duration is essential for tailoring treatment plans.

Clinicians should monitor emerging pharmacokinetic data to optimize patient comfort and minimize unwanted adverse events. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines.

Lens takeawayFormulation and dosing details must be tailored to individual patient physiology.

#### Safety & Side Effect Profile

Safety signals identified in this week’s literature scan reinforce the importance of screening for cytochrome P450 drug interactions, cardiovascular responses, and cognitive effects. Patient safety remains the primary clinical directive.

Documenting adverse event trends across diverse patient cohorts helps refine clinical protocols and risk-mitigation strategies. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines.

Lens takeawayRigorous safety screening protects patients against drug interactions and side effects.

#### Regulatory & Policy Dynamics

Health policy and regulatory updates from state licensing boards and federal agencies shape patient access, product testing standards, and dispensary packaging rules. Staying informed on legal frameworks ensures compliance and uninterrupted care access.

Policy developments directly influence research funding, product standardization, and clinical availability. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines.

Lens takeawayRegulatory compliance safeguards product quality and patient access protections. for patients, families, and healthcare providers across all clinical communities.

#### Mechanisms & Physiology

Preclinical studies from Europe PMC and OpenAlex provide valuable insights into CB1, CB2, TRPV1, and PPAR receptor pathways. While bench science does not equal clinical proof, it illuminates underlying physiological mechanisms.

Understanding biological mechanisms helps explain why patients report varied responses to identical cannabinoid formulations. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines.

Lens takeawayMechanistic insights explain physiological responses across different patient populations. for patients, families, and healthcare providers across all clinical communities.

#### Research Limitations

Critical evaluation of research methodologies reveals common limitations, including small sample sizes, short follow-up durations, and recall bias in self-reported surveys. Recognizing these boundaries prevents premature clinical extrapolation.

Rigorous study appraisal ensures that clinical recommendations are supported by robust, reproducible evidence. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines.

Lens takeawayIdentifying study limitations prevents premature clinical extrapolation of early data.

#### Future Outlook

Looking ahead, ongoing human clinical trials registered on ClinicalTrials.gov promise clearer guidance on cannabinoid efficacy and GLP-1 co-therapies. Monitoring trial progress prepares clinicians for upcoming therapeutic shifts.

Future publications will continue to refine evidence-based medical cannabis practices globally. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines.

Lens takeawayTracking ongoing trial registries prepares healthcare providers for future evidence shifts.

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.

 
 Health, Longevity, Wellness
 One-on-One Cannabis Guidance
 Metabolic Balance
 

 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](http://CEDclinic.com/book)
 [Cannabis Care](http://CEDclinic.com/book)
 
 

 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

Share this Evidence Watch

[X](https://twitter.com/intent/tweet?text=Weekly+Medical+Cannabis+%26+Science+Literature+Radar%3A+September+27%2C+2026&url=https%3A%2F%2Fcedclinic.com%2Fweekly-medical-cannabis-research-radar-2026-09-27%2F)
[LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fweekly-medical-cannabis-research-radar-2026-09-27%2F)
[BlueSky](https://bsky.app/intent/compose?text=Weekly+Medical+Cannabis+%26+Science+Literature+Radar%3A+September+27%2C+2026%20https%3A%2F%2Fcedclinic.com%2Fweekly-medical-cannabis-research-radar-2026-09-27%2F)
[Instagram](https://www.instagram.com/drcaplan/)
[Substack](https://doctorapprovedcannabis.substack.com/)
[RSS](https://cedclinic.com/feed/)

Source: [Primary Source: Cannabis use and route-specific administration among U.S. adults who do and do not use tobacco: Findings from the 2024 Health Information National Trends Survey.](https://pubmed.ncbi.nlm.nih.gov/42800375/)

Related Reading at CED ClinicContinue exploring the evidence[CED Clinic Medical Cannabis Education & Clinical Resources](https://cedclinic.com/education/)

Explore comprehensive clinical guides, dosing frameworks, and patient education materials from Dr. Caplan.

[Read Clinical Resources](https://cedclinic.com/education/)[Understanding Medical Cannabis Dosing and Formulation Ratios](https://cedclinic.com/dosing-guide/)

A clinical overview of cannabinoid titration, ratio selection, and administration methods for therapeutic care.

[View Dosing Guide](https://cedclinic.com/dosing-guide/)[Latest Medical Cannabis Science and Clinical Trial Reviews](https://cedclinic.com/category/cannabis-science/)

Browse CED Clinic’s archive of peer-reviewed study deep dives and clinical trial analyses.

[Browse Science Archive](https://cedclinic.com/category/cannabis-science/)

## Frequently Asked Questions

What is the CED Weekly Literature Radar?

The Weekly Literature Radar is a comprehensive weekly index produced by CED Clinic that aggregates, categorizes, and translates newly published medical cannabis and GLP-1 research from PubMed, Europe PMC, ClinicalTrials.gov, and OpenAlex.

How often is the Weekly Evidence Radar updated?

The Literature Radar is updated every week to capture newly published peer-reviewed studies, preprints, regulatory filings, and clinical trial registrations.

Why does CED Clinic summarize studies not covered in standalone articles?

Summarizing additional research ensures that patients and clinicians have access to a complete, transparent overview of all emerging scientific data, even for smaller pilot trials or preliminary preprints.

How are research studies selected for the Weekly Radar?

Studies are automatically ingested via API integrations with PubMed, Europe PMC, ClinicalTrials.gov, and OpenAlex, then filtered for clinical relevance, methodology, and primary source verification.

What is the Headline vs. Reality Truth Meter?

The Truth Meter is a specialized analysis card in every report that compares mainstream media news headlines against the actual data published in primary peer-reviewed journals.

Are preprints included in the Weekly Research Radar?

Yes, high-interest preprints from bioRxiv and medRxiv are included but are clearly labeled as preliminary data awaiting peer review.

How can clinicians use the Weekly Evidence Index?

Healthcare providers can use the index as a quick-reference literature scan to stay informed on emerging cannabinoid dosing, drug interactions, and clinical trial results.

Does the Weekly Radar cover GLP-1 medications?

Yes, the radar tracks clinical studies involving GLP-1 receptor agonists (semaglutide, tirzepatide) and their intersection with metabolic health, appetite, and substance use.

Where can I read the full text of studies listed in the radar?

Each study listed in the radar includes direct links to its PubMed PMID, DOI, or open-access repository URL for primary source verification.

How does CED Clinic evaluate study quality?

CED Clinic evaluates studies based on study design (RCT vs. observational), sample size, blinding, control groups, and potential sources of bias or funding conflict.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).